Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Journal
BMC cancer
Journal Volume
22
Journal Issue
1
Date Issued
2022-10-21
Author(s)
Abstract
Cancer therapy has evolved from non-specific cytotoxic agents to a selective, mechanism-based approach that includes targeted agents and immunotherapy. Although the response to targeted therapies for unresectable hepatocellular carcinoma (HCC) is acceptable with the improved survival, the high tumor recurrence rate and drug-related side effects continue to be problematic. Given that immune checkpoint inhibitor alone are not robust enough to improve survival in unresectable HCC, growing evidence supports the combination of targeted therapy and immunotherapy with synergistic effect.
Subjects
Immunotherapy; Meta-analysis; Systematic review; Targeted therapy; Unresectable hepatocellular carcinoma
SDGs
Publisher
BMC
Type
journal article